克雷西 发自 凹非寺 量子位 | 公众号 QbitAI 注意看，这些人正在用意念玩马里奥赛车。 他们的手没有动一下， 靠脑电波控制就完成了移动、转弯、吃道具等一系列动作 。 帮助他们通过"心灵感应"完成游戏操作的，就是马斯克Neuralink的脑机接口N1。 这就是Neuralink夏季更新报告会上，马斯克展示的最新成果。 截止目前，N1已经有七名受试者，他们以视频等形式分享了脑机接口对他们生活的改变。 这一个个真实案例，也获得了网友们的一片赞许。 同时，在这次报告会上，Neuralink也曝光了未来三年的发展路线—— 到2028年，Neuralink计划实现对大脑的全面访问。 让受试者重回生活 这七位受试者当中，有四位是脊髓损伤患者，另外三位是肌萎缩侧索硬化症（渐冻症）患者。 他们接受测试的地点不是在实验室，而是每天在家中使用Neuralink脑机接口设备，据统计， 他们平均每周使用脑机接口的时间长达50小时， 峰值甚至超过100小时，几乎覆盖了所有的清醒时间。 其中， Noland 是全球第一位N1受试者，他因为脊髓损伤瘫痪。 Noland装上N1之后当天，就学会了完全靠意念控制电脑光标，并打破了世界纪录 ...

Core Viewpoint - Zhiyun Health (09955) reported a revenue of 3.488 billion RMB for the fiscal year ending December 31, 2024, with a gross profit of 862 million RMB and a stable gross margin of 24.7%, reflecting a year-on-year increase of 0.1 percentage points [1] Financial Performance - The increase in overall gross margin is attributed to the improvement in the gross margin of outpatient solutions, which rose from 14.2% for the year ending December 31, 2023, to 23.1% for the year ending December 31, 2024 [1] - The net profit of the five subsidiaries involved in the divestitures totaled 99.6 million RMB (pre-tax) for the fiscal year ending December 31, 2024 [6] Divestiture Details - On March 30, 2025, Zhiyun Health's subsidiary, Hangzhou Kangsheng Health Management Consulting Co., Ltd., agreed to sell 55% of Zhejiang Qilian Pharmaceutical Co., Ltd. for 33.5164 million RMB [1] - The company also agreed to sell 30% of Jiangsu Xinwange Medical Technology Co., Ltd. for 32 million RMB and 65% of Jiangsu Wandi Biotechnology Co., Ltd. for 3 million RMB [3] - Additionally, 75% of Lianyungang Zhenghe Scientific Instrument Co., Ltd. was sold for 8 million RMB, and 35% of Jiangsu Chengsheng Gene Precision Medical Technology Co., Ltd. was sold for 3 million RMB [4] Strategic Rationale - The divestitures align with the company's long-term strategy focusing on AI-driven SaaS technology advancements and monetizing the P2M (Patient to Manufacturer) pipeline [1] - The decision to divest is driven by strategic and operational considerations, particularly the need to optimize the P2M strategy and integrate AI as part of the company's transformation efforts [4] Market Impact - The five subsidiaries involved in the divestitures are significantly affected by the national medical insurance bureau's procurement policies, which have led to price reductions in their products [5] - The anticipated sixth batch of high-value medical consumables procurement and the eleventh batch of drug procurement by the national medical insurance bureau in 2025 is expected to adversely impact the future revenue, profit, and asset quality of these subsidiaries [5]